41433-81-2

Usage

Uses

Used in Perfumery and Cosmetics Industry:
DIETHYL N-HEXADECYLMALONATE is used as a flavoring agent and fragrance ingredient for its fruity and floral scent, enhancing the sensory experience of perfumes, soaps, and cosmetics.
Used in Pharmaceutical Industry:
DIETHYL N-HEXADECYLMALONATE is used in the manufacturing of pharmaceuticals, contributing to the development of new medications and improving the sensory attributes of existing products.
Used in Plastics and Rubbers Industry:
DIETHYL N-HEXADECYLMALONATE is used as a lubricant in the production of plastics and rubbers, improving the processing and performance characteristics of these materials.
Used in Antioxidant and Antimicrobial Applications:
DIETHYL N-HEXADECYLMALONATE is used for its potential antioxidant and antimicrobial properties, providing additional benefits in various industries, including food preservation, personal care products, and medical applications.
It is important to handle DIETHYL N-HEXADECYLMALONATE with care and follow safety guidelines to minimize potential hazards associated with its use.

InChI:InChI=1/C23H44O4/c1-4-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21(22(24)26-5-2)23(25)27-6-3/h21H,4-20H2,1-3H3

Upstream product

• 111-61-5 stearic acid ethyl ester 
• 141-52-6 sodium ethanolate 
• 105-58-8 Diethyl carbonate 
• 112-82-3 hexadecanyl bromide 
• 105-53-3 diethyl malonate 
• 996-82-7 sodium diethylmalonate 
• 95-92-1 oxalic acid diethyl ester 

Downstream Products

• 89547-15-9 2-hexadecyloctadecanoic acid 
• 4371-64-6 n-hexadecylmalonic acid 
• 1221575-18-3 2-[(hexadecylamino)carbonyl]octadecanoic acid 
• 96563-17-6 4,4'-(2-hexadecyl-1,3-propanediyl)bis<10-<(4-methylphenyl)sulfonyl>-1,7-dioxa-4,10-diazacyclododecane> 
• 96563-16-5 2-hexadecylpropane-1,3-diol bis(4-methylbenzenesulfonate) 
• 91662-79-2 1-O-Benzyl-2-n-hexadecylpropan-1,3-diol-3-phosphorsaeure-2'-bromethylester 
• 91662-78-1 1-O-Benzyl-2-n-hexadecylpropan-1,3-diol 

Relevant academic research and scientific papers

Synthesis, characterization and blood compatibilities of novel segmented polyurethanes containing poly (butadiene) soft segments and phosphatidylcholine analogues in the main chains and long-chain alkyl groups in the side chains

New segmented polyurethanes (SPUs) containing poly(butadiene) (PBD) soft segments and phospholipid moieties in the main chains and long-chain alkyl groups in the side chains were synthesized. The phospholipid moieties include bis [2-(2-hydroxyethyldimethylammonio)ethyl] 2-octylpropane- 1,3-diyl bis(phosphate) (OcPDP), bis [2-(2-hydroxyethyldimethylammonio)ethyl]2- oleylpropane-1,3-diyl bis (phosphate) (O1PDP) and bis[2-(2- hydroxyethyldimethylammonio)ethyl] 2-cetylpropane-1,3-diyl bis(phosphate) (CPDP). The bulk characterization of synthesized SPUs was investigated by infrared (IR) spectroscopy and gel-permeation chromatography (GPC). The mechanical properties were evaluated by dynamic viscoelasticity and tensile measurements. The existence of phospholipid analogous groups on the surface of these SPUs was revealed by attenuated total reflection Fourier transform infrared spectroscopy (ATR-FTIR), X-ray photoelectron spectroscopy (XPS) and contact angle measurements. The blood compatibilities of the new polymers were evaluated by platelet rich plasma (PRP) contact studies and viewed by scanning electron microscopy (SEM) using medical grade BioSpan and non- phospholipid polyurethane as references. These new materials have good surfaces in terms of platelet adhesion, and the morphology of adhered platelets undergoes a relatively low degree of variation.

General synthesis and physicochemical characterisation of a series of peptide-mimic lysine-based amino-functionalised lipids

A series of novel malonic acid diamides (second generation) with two long hydrophobic alkyl chains and an alkaline polar head group was synthesised and characterised as a new class of amino-functionalised lipids. These peptide-mimic lipids are suitable for polynucleotide transfer. The lipids bear a novel backbone consisting of a lysine unit and a malonic acid unit. Six different head-group structures, which vary in size and number of amino groups that can be protonated, were attached to the backbone structure. Furthermore, different alkyl chains were used to build the lipophilic part (namely tetradecyl, hexadecyl, and oleyl). Phase transitions of the new compounds in aqueous dispersions at pHa 10 were analysed and discussed in terms of head group and alkyl chain variations. The shape and size of the formed aggregates of selected lipid dispersions were investigated by dynamic light scattering and transmission electron microscopy. Copycats: Malonic acid diamides, a new class of amino-functionalised lipids, have been synthesised and characterised. These peptide-mimic lipids are suitable for polynucleotide transfer. Six head-group structures, which vary in size and number of amino groups, are used. The modularly composed synthesis of the backbone allows easy alkyl-chain variation (see figure). Phase transitions are discussed in terms of head-group and alkyl-chain variations. Copyright

Synthesis of new lipophilic Ortho-dicarboranes

The synthesis of several new lipoidal dicarborane compounds prepared by reaction of decaborane with several fatty mona- and bis-alkyl-1,3-diols is described.

Unsymmetrical spiroalkanedithiols having mixed fluorinated and alkyl tailgroups of varying length: Film structure and interfacial properties

A custom-designed series of unsymmetrical spiroalkanedithiols having tailgroups comprised of a terminally fluorinated chain and a hydrocarbon chain of varying lengths were synthesized and used to prepare self-assembled monolayers (SAMs) on gold substrates. The specific structure of the adsorbates was of the form [CH3(CH2)n][CF3(CF2)7(CH2)8]C[CH2SH]2, where n = 7, 9, and 15 (designated as F8H10-C10, F8H10-C12, and F8H10-C18, respectively). The influence of the length of the hydrocarbon chain in the bidentate dithiol on the structure and interfacial properties of the monolayer was explored. A structurally analogous partially fluorinated monodentate alkanethiol and the corresponding normal alkanethiols were used to generate appropriate SAMs as reference systems. Measurements of ellipsometric thickness showed an unexpectedly low film thickness for the SAMs derived from the bidentate adsorbates, possibly due to disruptions in interchain packing caused by the fluorocarbon chains (i.e., phase-incompatible fluorocarbon-hydrocarbon interactions), ultimately giving rise to loosely packed and disordered films. Analysis by X-ray photoelectron spectroscopy (XPS) were also consistent with a model in which the films were loosely packed; additionally, the XPS spectra confirmed the attachment of the sulfur headgroups of the bidentate adsorbates onto the gold substrates. Studies of the SAMs by polarization modulation-infrared reflection-adsorption spectroscopy (PM-IRRAS) suggested that as the length of the hydrocarbon chain in the adsorbates was extended, a more ordered surface was achieved by reducing the tilt of the fluorocarbon segment. The wettability data indicated that the adsorbates with longer alkyl chains were less wettable than those with shorter alkyl chains, likely due to an increase in interchain van der Waals forces in the former.

4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO

Disclosed are halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections. Such viral infections can include tongaviridae, bunyaviridae, arenaviridae, coronaviridae, flaviviridae, picornaviridae, Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infections.

4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO

Disclosed are halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections. Such viral infections can include tongaviridae, bunyaviridae, arenaviridae, coronaviridae, flaviviridae, picornaviridae, Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infections.

NOVEL XYLENE-BASED AMPHIPHILIC COMPOUND AND USE THEREOF

The present invention relates to a xylene-based amphiphilic compound, a method for preparing the same, and a method for extracting, solubilizing, stabilizing or crystallizing a membrane protein using the same. By using the xylene-based compound according to the present invention, a membrane protein may be stably stored in an aqueous solution for a long time, and may be applied in functional and structural analyses. The structural and functional analysis of the membrane protein is one of the fields of highest interest in biology and chemistry, and the xylene-based compound according to the present invention can be applied in research on protein structure that is closely related to development of a new drug.

NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO

This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether.

NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO

This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether.

ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO

This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether.